Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
CA 2109727 C · Owner: Boon, Thierry · Inventors: Boon, Thierry; Van Der Bruggen, Pierre; Lurquin, Christophe
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 22, 1992 and granted July 25, 2000. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 22, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 22, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.